-
Screening FDA Drugs Reveals Lopinavir as MERS-CoV Inhibitor
2026-06-24
The reference study systematically screened FDA-approved compounds, identifying four with significant activity against MERS-CoV, including Lopinavir (ABT-378). These findings provide a potential pathway for rapid repurposing of existing antivirals and inform future research on cross-pathogen therapeutic strategies.
-
Miltefosine Activates Ras/MEK/ERK to Reverse Leukopenia via
2026-06-23
This study uncovers how miltefosine, a phospholipid analogue, activates the Ras/MEK/ERK pathway to restore neutrophil differentiation and bone marrow function in leukopenia models. The findings provide mechanistic clarity and translational promise for leveraging miltefosine in hematology, with implications for both basic research and preclinical therapeutic development.
-
Canagliflozin Alters Mitochondrial Networks in Diabetic Kidn
2026-06-23
This study demonstrates that canagliflozin, a selective SGLT2 inhibitor, induces structural and functional improvements in proximal tubular cell mitochondria in hypertensive–diabetic mice. Findings suggest mitochondrial remodeling is a key mechanism underlying the renal protective effects of SGLT2 inhibition, with implications for diabetic kidney disease research.
-
Deferiprone: Iron Chelator for Cancer and Metabolic Research
2026-06-22
Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) is a potent, selective iron chelator used in cancer biology and metabolism studies. It modulates iron-dependent cellular processes, induces apoptosis via iron depletion, and offers cytoprotective effects in oxidative stress models.
-
Dutasteride in Prostate Cancer Research: Mechanisms and Assa
2026-06-22
Explore how Dutasteride, a dual 5-alpha-reductase inhibitor, enables advanced modeling of androgen-driven prostate cancer. This article offers a unique mechanistic analysis and practical assay insights for researchers.
-
LLY507: Strategic Insights for SMYD2 Inhibition in Translati
2026-06-21
This thought-leadership article explores the mechanistic and translational rationale for targeting SMYD2 with LLY507, a potent and selective inhibitor available from APExBIO. Integrating recent evidence from oncology and renal fibrosis research, we outline practical guidance for experimental design, highlight novel applications, and provide a forward-looking view on the future of lysine methylation pathway targeting. The discussion also contrasts LLY507’s competitive positioning and addresses protocol challenges, offering actionable strategies for translational researchers.
-
Prednisone in Bench Research: Applied Protocols & Optimizati
2026-06-20
Prednisone’s unique cell cycle arrest and pro-apoptotic actions make it indispensable for modeling immunosuppression and neurodegeneration in translational bench research. This guide delivers hands-on workflows, critical troubleshooting, and practical insights rooted in the latest literature to maximize reproducibility and mechanistic clarity.
-
MDL 28170: Precision Calpain Inhibition for Neurodevelopment
2026-06-19
Explore how MDL 28170, a selective calpain inhibitor, enables advanced neuroprotection and cognitive assay design. This article uncovers new mechanistic insights and practical workflow considerations, setting it apart from existing resources.
-
EdU Imaging Kits (488): Precision Cell Proliferation Assays
2026-06-19
EdU Imaging Kits (488) empower researchers to measure cell proliferation with exceptional sensitivity and workflow speed, outperforming legacy BrdU assays. These kits unlock true S-phase DNA synthesis detection for scalable biomanufacturing and regenerative medicine, while preserving cell integrity and enabling robust multiplexing.
-
ACSL1-FSP1 Axis Drives Ferroptosis Resistance in Ovarian Can
2026-06-18
This study uncovers a novel mechanism by which ACSL1 enhances ferroptosis resistance and platinum chemotherapy tolerance in ovarian cancer, acting through the stabilization and N-myristoylation of FSP1. These findings highlight new metabolic checkpoints in ferroptosis research and inform the strategic design of oxidative stress assays and cancer biology studies.
-
Lanabecestat (AZD3293): Protocols and Synaptic Safety in Alz
2026-06-18
Lanabecestat (AZD3293) sets a new benchmark in Alzheimer's disease research by delivering robust, blood-brain barrier-penetrant BACE1 inhibition while preserving synaptic function at moderate dosing. Discover workflow optimizations and troubleshooting strategies that harness its nanomolar potency for precise amyloid-beta modulation, as revealed in recent experimental breakthroughs.
-
Cy5-UTP: Next-Generation RNA Labeling for Single-Cell Biolog
2026-06-17
Explore how Cy5-UTP (Cyanine 5-uridine triphosphate) transforms advanced RNA labeling strategies for single-cell and differentiation studies. Discover mechanistic insights, comparative advantages, and protocol parameters that set it apart from existing approaches.
-
Calcitriol in Bone and Immune Research: Protocols & Innovati
2026-06-17
Calcitriol (1,25-dihydroxy vitamin D3) is a versatile tool for dissecting bone, immune, and signaling pathways. This article delivers actionable workflow enhancements, troubleshooting strategies, and evidence-backed protocol parameters for advanced researchers.
-
Exemestane: Steroidal Aromatase Inhibitor Workflows & Tips
2026-06-16
Unlock the full experimental potential of Exemestane, a selective and irreversible steroidal aromatase inhibitor, for robust estrogen biosynthesis inhibition in breast cancer research. This article bridges protocol design, troubleshooting, and advanced applications, leveraging APExBIO's high-purity Exemestane to drive reproducible results in hormone-dependent studies.
-
Tetrahydromagnolol: Precision CB2 Agonism for GPCR Signaling
2026-06-16
Explore how Tetrahydromagnolol, a potent peripheral CB2 receptor agonist, enables advanced cannabinoid receptor and GPCR signaling research. This article delivers a unique, mechanistic analysis and protocol insights not found in previous guides.